Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systemic mastocytosis with chronic myelomonocytic leukemia followed by transformation into acute myeloid leukemia

Systemic mastocytosis with chronic myelomonocytic leukemia followed by transformation into acute... AbstractIntroductionSystemic mastocytosis (SM) with an associated hematological neoplasm (SM-AHN) constitutes about 40% of all patients with SM. AHN commonly includes myeloid neoplasms and chronic myelomonocytic leukemia (CMML) is seen in about 30% of these patients.Case reportA 67-year-old male presented to hematologist with fatigue and significant weight loss. Abdominal ultrasound and computed tomography (CT) detected hepatosplenomegaly, abdominal lymphadenopathy, and ascites. He was anemic with leukocytosis and eosinophilia. Trephine biopsy showed > 30% of spindle-shaped mast cells. The KITD816V mutation was present. Serum tryptase level was elevated to 62 ng/mL. The patient was diagnosed with aggressive SM and received six cycles of cladribine with partial response. Three years later, he developed severe anemia. Eosinophilia and monocytosis (5.6 × 109/L) were demonstrated in blood film. Hepatosplenomegaly and abdominal lymphadenopathy were also present. Trephine biopsy did not demonstrate the presence of spindle-shaped mast cells, but dysplasia in erythroid and myeloid lineages was evident. The histological result of lymph node biopsy as well as blood and bone marrow findings were in line with CMML. He received hydroxyurea, but he transformed soon into fatal acute monocytic leukemia.ConclusionsThe prognosis of SM-AHN depends on AHN component. Leukemic transformation of AHN component may occur in a proportion of patients. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Polonica de Gruyter

Systemic mastocytosis with chronic myelomonocytic leukemia followed by transformation into acute myeloid leukemia

Download PDF
5 pages

Loading next page...
 
/lp/de-gruyter/systemic-mastocytosis-with-chronic-myelomonocytic-leukemia-followed-by-yfJawAUJr3
Publisher
de Gruyter
Copyright
© 2020 Marta Panz-Klapuch et al., published by Sciendo
eISSN
2300-7117
DOI
10.2478/ahp-2020-0011
Publisher site
See Article on Publisher Site

Abstract

AbstractIntroductionSystemic mastocytosis (SM) with an associated hematological neoplasm (SM-AHN) constitutes about 40% of all patients with SM. AHN commonly includes myeloid neoplasms and chronic myelomonocytic leukemia (CMML) is seen in about 30% of these patients.Case reportA 67-year-old male presented to hematologist with fatigue and significant weight loss. Abdominal ultrasound and computed tomography (CT) detected hepatosplenomegaly, abdominal lymphadenopathy, and ascites. He was anemic with leukocytosis and eosinophilia. Trephine biopsy showed > 30% of spindle-shaped mast cells. The KITD816V mutation was present. Serum tryptase level was elevated to 62 ng/mL. The patient was diagnosed with aggressive SM and received six cycles of cladribine with partial response. Three years later, he developed severe anemia. Eosinophilia and monocytosis (5.6 × 109/L) were demonstrated in blood film. Hepatosplenomegaly and abdominal lymphadenopathy were also present. Trephine biopsy did not demonstrate the presence of spindle-shaped mast cells, but dysplasia in erythroid and myeloid lineages was evident. The histological result of lymph node biopsy as well as blood and bone marrow findings were in line with CMML. He received hydroxyurea, but he transformed soon into fatal acute monocytic leukemia.ConclusionsThe prognosis of SM-AHN depends on AHN component. Leukemic transformation of AHN component may occur in a proportion of patients.

Journal

Acta Haematologica Polonica – de Gruyter

Published: Mar 1, 2020

References

  • Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
  • International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
  • Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
  • Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
  • Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
  • Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components
  • Mastocytosis
  • Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
  • Cladribine therapy for systemic mastocytosis
  • Impact of somatic and germline mutations on the outcome of systemic mastocytosis
  • Systemic mastocytosis in association with small lymphocytic lymphoma
  • Efficacy and safety of midostaurin in advanced systemic mastocytosis
  • Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
  • Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
  • Impact of somatic and germline mutations on the outcome of systemic mastocytosis
  • Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
  • Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance
  • Mastocytosis
  • Systemic mastocytosis with associated clonal haematological non-mast cell lineage disease: a histopathological challenge
  • Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
  • Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
  • Significance of systemic mast cell disease with associated hematologic disorders
  • Epidemiology, prognosis, and risk factors in mastocytosis
  • Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components
  • Efficacy and safety of midostaurin in advanced systemic mastocytosis
  • Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
  • Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from a single-cell analysis of mutations in the c-kit gene
  • Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
  • Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
  • Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from a single-cell analysis of mutations in the c-kit gene
  • Epidemiology, prognosis, and risk factors in mastocytosis
  • Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
  • Significance of systemic mast cell disease with associated hematologic disorders
  • Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance
  • Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
  • International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis
  • Systemic mastocytosis with associated clonal haematological non-mast cell lineage disease: a histopathological challenge
  • Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
  • Systemic mastocytosis in association with small lymphocytic lymphoma
  • Cladribine therapy for systemic mastocytosis